BIRB796, an Inhibitor of p38 Mitogen-Activated Protein Kinase, Inhibits Proliferation and Invasion in Glioblastoma Cells
Open Access
- 22 April 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (17) , 11466-11473
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81372683, 81502075, 81572489)
This publication has 31 references indexed in Scilit:
- BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression CellsPLOS ONE, 2013
- Signal integration by JNK and p38 MAPK pathways in cancer developmentNature Reviews Cancer, 2009
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- MAP-ing glioma invasion: Mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survivalMolecular Cancer Therapeutics, 2007
- Ethanol reduces p38 kinase activation and cyclin D1 protein expression after partial hepatectomy in ratsJournal of Hepatology, 2006
- BIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in VivoJournal of Biological Chemistry, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Activation and signaling of the p38 MAP kinase pathwayCell Research, 2005
- Matrix metalloproteinasesEuropean Journal of Cancer, 2000
- Protein Kinase C-δ Associates with Vimentin Intermediate Filaments in Differentiated HL60 CellsExperimental Cell Research, 1996